Sodium Zirconium Cyclosilicate Generics Suppliers & Bulk Manufacturers
Available Forms: Powder for oral suspension
Available Strengths: 5g, 7g,10g sachets
Reference Brands: Lokelma® (EU & US)
Category:
Nephrology
Sodium Zirconium Cyclosilicate (SZC), marketed as Lokelma®, is a fast-acting, selective potassium binder used to treat hyperkalemia in CKD and heart failure patients. Approved in the EU and US, it is supplied as a powder for oral suspension in 5 g and 10 g sachets.
Sodium Zirconium Cyclosilicate Generics is available in Powder for oral suspension
and strengths such as 5g, 7g,10g sachets.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sodium Zirconium Cyclosilicate Generics is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sodium Zirconium Cyclosilicate Generics can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sodium Zirconium Cyclosilicate (SZC), marketed as Lokelma®, is a novel, highly selective potassium binder used to treat hyperkalemia in patients with chronic kidney disease, heart failure, or those on RAAS inhibitors. Approved by the FDA and EMA, it offers rapid onset and sustained potassium control with excellent tolerability. Available as a powder for oral suspension in 5 g and 10 g strengths, SZC is in high demand across EU and US pharmaceutical B2B markets. Ideal for licensing, distribution, and contract manufacturing partnerships, SZC represents a valuable addition to renal and cardiovascular therapeutic portfolios in regulated international markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing